Pharmakokinetics of Mistletoe Lectins after Intravenous Application of a Mistletoe Product in Healthy Subjects
Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for supportive cancer treatment. MP are also given off-label intravenously, but data about pharmacokinetics are widely lacking. Therefore, the aim of...
Saved in:
| Published in | Pharmaceuticals (Basel, Switzerland) Vol. 17; no. 3; p. 278 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
22.02.2024
MDPI |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for supportive cancer treatment. MP are also given off-label intravenously, but data about pharmacokinetics are widely lacking. Therefore, the aim of our phase I trial was to evaluate the pharmacokinetics and safety of intravenously applied natural ML. Initially, 12 healthy male volunteers were planned to receive a single infusion of 2000 mg Helixor
P. We had to terminate the study prematurely after the inclusion of eight subjects due to elevation of all subjects' liver enzymes. ML was detected in all subjects after infusion. The mean half-life of serum ML was 7.02 ± 2.01 h. Mean alanine transaminase increased from 23 ± 6 to a maximum of 445 ± 260 U/L, and mean aspartate aminotransferase increased from 24 ± 3 to a maximum of 318 ± 33 U/L 72 h after infusion. Severity grading for drug-induced liver injury was mild. Participants did not suffer from any liver-specific symptoms and recovered completely. As a conclusion, the dose of 2000 mg Helixor
P caused transient liver injury in healthy subjects and should, therefore, not be used for initial patient treatment. Liver enzymes should be monitored in patients receiving intravenous treatment with Helixor
P. |
|---|---|
| AbstractList | Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for supportive cancer treatment. MP are also given off-label intravenously, but data about pharmacokinetics are widely lacking. Therefore, the aim of our phase I trial was to evaluate the pharmacokinetics and safety of intravenously applied natural ML. Initially, 12 healthy male volunteers were planned to receive a single infusion of 2000 mg Helixor® P. We had to terminate the study prematurely after the inclusion of eight subjects due to elevation of all subjects’ liver enzymes. ML was detected in all subjects after infusion. The mean half-life of serum ML was 7.02 ± 2.01 h. Mean alanine transaminase increased from 23 ± 6 to a maximum of 445 ± 260 U/L, and mean aspartate aminotransferase increased from 24 ± 3 to a maximum of 318 ± 33 U/L 72 h after infusion. Severity grading for drug-induced liver injury was mild. Participants did not suffer from any liver-specific symptoms and recovered completely. As a conclusion, the dose of 2000 mg Helixor® P caused transient liver injury in healthy subjects and should, therefore, not be used for initial patient treatment. Liver enzymes should be monitored in patients receiving intravenous treatment with Helixor® P. Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for supportive cancer treatment. MP are also given off-label intravenously, but data about pharmacokinetics are widely lacking. Therefore, the aim of our phase I trial was to evaluate the pharmacokinetics and safety of intravenously applied natural ML. Initially, 12 healthy male volunteers were planned to receive a single infusion of 2000 mg Helixor P. We had to terminate the study prematurely after the inclusion of eight subjects due to elevation of all subjects' liver enzymes. ML was detected in all subjects after infusion. The mean half-life of serum ML was 7.02 ± 2.01 h. Mean alanine transaminase increased from 23 ± 6 to a maximum of 445 ± 260 U/L, and mean aspartate aminotransferase increased from 24 ± 3 to a maximum of 318 ± 33 U/L 72 h after infusion. Severity grading for drug-induced liver injury was mild. Participants did not suffer from any liver-specific symptoms and recovered completely. As a conclusion, the dose of 2000 mg Helixor P caused transient liver injury in healthy subjects and should, therefore, not be used for initial patient treatment. Liver enzymes should be monitored in patients receiving intravenous treatment with Helixor P. Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for supportive cancer treatment. MP are also given off-label intravenously, but data about pharmacokinetics are widely lacking. Therefore, the aim of our phase I trial was to evaluate the pharmacokinetics and safety of intravenously applied natural ML. Initially, 12 healthy male volunteers were planned to receive a single infusion of 2000 mg Helixor[sup.®] P. We had to terminate the study prematurely after the inclusion of eight subjects due to elevation of all subjects’ liver enzymes. ML was detected in all subjects after infusion. The mean half-life of serum ML was 7.02 ± 2.01 h. Mean alanine transaminase increased from 23 ± 6 to a maximum of 445 ± 260 U/L, and mean aspartate aminotransferase increased from 24 ± 3 to a maximum of 318 ± 33 U/L 72 h after infusion. Severity grading for drug-induced liver injury was mild. Participants did not suffer from any liver-specific symptoms and recovered completely. As a conclusion, the dose of 2000 mg Helixor[sup.®] P caused transient liver injury in healthy subjects and should, therefore, not be used for initial patient treatment. Liver enzymes should be monitored in patients receiving intravenous treatment with Helixor[sup.®] P. Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for supportive cancer treatment. MP are also given off-label intravenously, but data about pharmacokinetics are widely lacking. Therefore, the aim of our phase I trial was to evaluate the pharmacokinetics and safety of intravenously applied natural ML. Initially, 12 healthy male volunteers were planned to receive a single infusion of 2000 mg Helixor ® P. We had to terminate the study prematurely after the inclusion of eight subjects due to elevation of all subjects’ liver enzymes. ML was detected in all subjects after infusion. The mean half-life of serum ML was 7.02 ± 2.01 h. Mean alanine transaminase increased from 23 ± 6 to a maximum of 445 ± 260 U/L, and mean aspartate aminotransferase increased from 24 ± 3 to a maximum of 318 ± 33 U/L 72 h after infusion. Severity grading for drug-induced liver injury was mild. Participants did not suffer from any liver-specific symptoms and recovered completely. As a conclusion, the dose of 2000 mg Helixor ® P caused transient liver injury in healthy subjects and should, therefore, not be used for initial patient treatment. Liver enzymes should be monitored in patients receiving intravenous treatment with Helixor ® P. |
| Audience | Academic |
| Author | Rieger, Sabine Lederer, Ann-Kathrin Huber, Roman Schink, Michael |
| AuthorAffiliation | 3 Helixor Heilmittel GmbH, Fischermühle 1, 72348 Rosenfeld, Germany 2 Department of General, Visceral and Transplant Surgery, University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany 1 Center for Complementary Medicine, Department of Internal Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg im Breisgau, Germany |
| AuthorAffiliation_xml | – name: 2 Department of General, Visceral and Transplant Surgery, University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany – name: 3 Helixor Heilmittel GmbH, Fischermühle 1, 72348 Rosenfeld, Germany – name: 1 Center for Complementary Medicine, Department of Internal Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg im Breisgau, Germany |
| Author_xml | – sequence: 1 givenname: Ann-Kathrin orcidid: 0000-0001-7984-9530 surname: Lederer fullname: Lederer, Ann-Kathrin organization: Department of General, Visceral and Transplant Surgery, University Medical Center, Johannes Gutenberg University, 55131 Mainz, Germany – sequence: 2 givenname: Sabine surname: Rieger fullname: Rieger, Sabine organization: Helixor Heilmittel GmbH, Fischermühle 1, 72348 Rosenfeld, Germany – sequence: 3 givenname: Michael surname: Schink fullname: Schink, Michael organization: Helixor Heilmittel GmbH, Fischermühle 1, 72348 Rosenfeld, Germany – sequence: 4 givenname: Roman surname: Huber fullname: Huber, Roman organization: Center for Complementary Medicine, Department of Internal Medicine II, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg im Breisgau, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38543063$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkl9vFCEUxSemxv7RFz-AmcQXY7IVBhiYJ7Np1G6yxibqMwHmsst2FlZgmvTby7i13TWGB8jldw85h3tenfjgoapeY3RJSIc-7NaYI4IaLp5VZ5g2dCYayk8OzqfVeUobhBjHFL-oTolglKCWnFX-Zq3iVt2GW-chO5PqYOuvLuUBcoB6CSY7n2plM8R64XNUd-DDmOr5bjc4o7ILfmpRB003MfSjybXz9TWoIa_v6--j3hSp9LJ6btWQ4NXDflH9_Pzpx9X1bPnty-JqvpwZ2nV5RjmnghuBDG44o0rhniFNraaUW8I7LaDYtdBirEjbd1QQxFjX0gKjpmHkolrsdfugNnIX3VbFexmUk38KIa6kisXuAFL0ivWKGiC6pVpzoRtrNAIhdN9xS4vWx73WbtRb6A1MKQxHosc33q3lKtxJjDrOSuRF4d2DQgy_RkhZbl0yMAzKQ8lSEoRp-Rza8oK-_QfdhDH6klWhECGMCcqeqJUqDpy3oTxsJlE550I0rMF8oi7_Q5XVw9aZMkPWlfpRw_t9g4khpQj20SRGcho1-TRqBX5zGMsj-ne2yG_Ukc8e |
| Cites_doi | 10.1007/s12272-020-01247-w 10.1093/annonc/mdh469 10.1002/jat.2876 10.1016/j.ctim.2018.01.002 10.1177/15347354221133561 10.1158/2767-9764.CRC-23-0002 10.1177/1534735416658121 10.1136/bmj.282.6265.739-b 10.1053/sonc.2002.50006 10.1007/s00228-010-0830-5 10.1007/978-3-662-26751-6 10.1038/nbt0492-405 10.1007/s00103-020-03122-x 10.1007/s00520-022-06921-x 10.1186/s12906-017-1971-1 10.1186/1472-6882-11-72 10.1016/0014-5793(88)80853-6 10.1177/15347354231198074 10.1016/S0140-6736(83)91706-3 10.1186/s12906-020-03013-3 10.1016/j.jff.2018.03.015 10.1136/bmj.282.6259.186 10.1016/j.fct.2019.04.044 10.29121/granthaalayah.v5.i10.2017.2306 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2024 MDPI AG 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 by the authors. 2024 |
| Copyright_xml | – notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 by the authors. 2024 |
| DBID | NPM AAYXX CITATION 3V. 7XB 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO GNUQQ GUQSH M2O MBDVC PIMPY PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.3390/ph17030278 |
| DatabaseName | PubMed CrossRef ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central ProQuest Central Student Research Library Prep ProQuest research library Research Library (Corporate) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | PubMed CrossRef Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Basic ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Research Library ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1424-8247 |
| ExternalDocumentID | oai_doaj_org_article_8da5da4ce3b64bb78b2fcb0e88bd97f4 A788252175 10_3390_ph17030278 38543063 |
| Genre | Journal Article |
| GeographicLocations | Germany |
| GeographicLocations_xml | – name: Germany |
| GrantInformation_xml | – fundername: Helixor Heilmittel (Germany) – fundername: Helixor Heilmittel GmbH grantid: 2021-UKF-HX-V1.0 |
| GroupedDBID | --- 2WC 3V. 53G 5VS 8G5 AADQD AAFWJ ABDBF ABUWG ACGFO ACIHN ADBBV AEAQA AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ CCPQU DIK DWQXO EBD ESX GNUQQ GROUPED_DOAJ GUQSH GX1 HH5 HYE IAO IHR ITC KQ8 M2O M48 MK0 MODMG M~E NPM OK1 P2P PGMZT PIMPY PQQKQ PROAC RIG RPM TUS AAYXX CITATION 7XB 8FK MBDVC PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c499t-477487c80c12754aa1d50b4fb447f379b8e027fe611a36d948305596475402253 |
| IEDL.DBID | RPM |
| ISSN | 1424-8247 |
| IngestDate | Thu Jul 04 21:11:52 EDT 2024 Tue Sep 17 21:29:16 EDT 2024 Sat Aug 17 05:39:20 EDT 2024 Tue Sep 24 20:53:28 EDT 2024 Wed Apr 10 18:03:10 EDT 2024 Tue Apr 16 05:12:17 EDT 2024 Thu Sep 26 16:04:03 EDT 2024 Sat Sep 28 08:02:04 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | pharmacokinetics reversible liver injury viscum album mistletoe lectins phase I clinical trial |
| Language | English |
| License | Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c499t-477487c80c12754aa1d50b4fb447f379b8e027fe611a36d948305596475402253 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-7984-9530 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10975571/ |
| PMID | 38543063 |
| PQID | 3003355845 |
| PQPubID | 2032350 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_8da5da4ce3b64bb78b2fcb0e88bd97f4 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10975571 proquest_miscellaneous_3014005467 proquest_journals_3003355845 gale_infotracmisc_A788252175 gale_infotracacademiconefile_A788252175 crossref_primary_10_3390_ph17030278 pubmed_primary_38543063 |
| PublicationCentury | 2000 |
| PublicationDate | 20240222 |
| PublicationDateYYYYMMDD | 2024-02-22 |
| PublicationDate_xml | – month: 2 year: 2024 text: 20240222 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Pharmaceuticals (Basel, Switzerland) |
| PublicationTitleAlternate | Pharmaceuticals (Basel) |
| PublicationYear | 2024 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Rostock (ref_1) 2020; 63 Ji (ref_13) 2017; 5 Steele (ref_11) 2014; 2014 Steele (ref_32) 2014; 2014 Paller (ref_14) 2023; 3 Stirpe (ref_19) 1992; 10 ref_10 Zuzak (ref_12) 2018; 40 Hyde (ref_26) 1981; 282 Harvey (ref_27) 1981; 282 Pelzer (ref_7) 2022; 30 ref_18 ref_16 Endo (ref_17) 1988; 231 Ewald (ref_9) 2017; 16 ref_15 Stirpe (ref_25) 1983; 321 Riggert (ref_21) 2004; 15 Loef (ref_8) 2023; 22 Mansky (ref_4) 2002; 29 ref_24 Szurpnicka (ref_2) 2020; 43 ref_23 Wan (ref_31) 2018; 44 Gong (ref_30) 2014; 34 ref_20 ref_3 ref_28 Wieczorek (ref_29) 2019; 129 Loef (ref_6) 2022; 21 Huber (ref_22) 2010; 66 ref_5 |
| References_xml | – volume: 43 start-page: 593 year: 2020 ident: ref_2 article-title: Biological activity of mistletoe: In vitro and in vivo studies and mechanisms of action publication-title: Arch. Pharm. Res. doi: 10.1007/s12272-020-01247-w contributor: fullname: Szurpnicka – volume: 15 start-page: 1816 year: 2004 ident: ref_21 article-title: Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: A study of the European Organization for Research and Treatment of Cancer New Drug Development Group publication-title: Ann. Oncol. doi: 10.1093/annonc/mdh469 contributor: fullname: Riggert – ident: ref_28 – ident: ref_24 – volume: 34 start-page: 265 year: 2014 ident: ref_30 article-title: Hepatoprotective effects of syringin on fulminant hepatic failure induced by D-galactosamine and lipopolysaccharide in mice publication-title: J. Appl. Toxicol. doi: 10.1002/jat.2876 contributor: fullname: Gong – volume: 40 start-page: 198 year: 2018 ident: ref_12 article-title: Safety of high-dose intravenous mistletoe therapy in pediatric cancer patients: A case series publication-title: Complement. Ther. Med. doi: 10.1016/j.ctim.2018.01.002 contributor: fullname: Zuzak – volume: 21 start-page: 153473542211335 year: 2022 ident: ref_6 article-title: Survival of Cancer Patients Treated with Non-Fermented Mistletoe Extract: A Systematic Review and Meta-Analysis publication-title: Integr. Cancer Ther. doi: 10.1177/15347354221133561 contributor: fullname: Loef – volume: 3 start-page: 338 year: 2023 ident: ref_14 article-title: Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer publication-title: Cancer Res. Commun. doi: 10.1158/2767-9764.CRC-23-0002 contributor: fullname: Paller – volume: 16 start-page: 479 year: 2017 ident: ref_9 article-title: Fever Therapy With Intravenously Applied Mistletoe Extracts for Cancer Patients: A Retrospective Study publication-title: Integr. Cancer Ther. doi: 10.1177/1534735416658121 contributor: fullname: Ewald – volume: 282 start-page: 739 year: 1981 ident: ref_26 article-title: Mistletoe hepatitis publication-title: BMJ doi: 10.1136/bmj.282.6265.739-b contributor: fullname: Hyde – volume: 29 start-page: 589 year: 2002 ident: ref_4 article-title: Mistletoe and cancer: Controversies and perspectives publication-title: Semin. Oncol. doi: 10.1053/sonc.2002.50006 contributor: fullname: Mansky – volume: 66 start-page: 889 year: 2010 ident: ref_22 article-title: Pharmacokinetics of natural mistletoe lectins after subcutaneous injection publication-title: Eur. J. Clin. Pharmacol. doi: 10.1007/s00228-010-0830-5 contributor: fullname: Huber – ident: ref_16 doi: 10.1007/978-3-662-26751-6 – ident: ref_18 – volume: 10 start-page: 405 year: 1992 ident: ref_19 article-title: Ribosome–Inactivating Proteins from Plants: Present Status and Future Prospects publication-title: Bio/Technology doi: 10.1038/nbt0492-405 contributor: fullname: Stirpe – ident: ref_23 – volume: 63 start-page: 535 year: 2020 ident: ref_1 article-title: Die Misteltherapie in der Behandlung von Patienten mit einer Krebserkrankung publication-title: Bundesgesundheitsblatt-Gesundheitsforsch.-Gesundheitsschutz doi: 10.1007/s00103-020-03122-x contributor: fullname: Rostock – volume: 2014 start-page: 1 year: 2014 ident: ref_11 article-title: Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients publication-title: Evidence-Based Complement. Altern. Med. contributor: fullname: Steele – volume: 30 start-page: 6405 year: 2022 ident: ref_7 article-title: Cancer-related fatigue in patients treated with mistletoe extracts: A systematic review and meta-analysis publication-title: Support. Care Cancer doi: 10.1007/s00520-022-06921-x contributor: fullname: Pelzer – ident: ref_10 doi: 10.1186/s12906-017-1971-1 – ident: ref_3 doi: 10.1186/1472-6882-11-72 – volume: 231 start-page: 378 year: 1988 ident: ref_17 article-title: The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes The RNA N-glycosidase activity of the protein publication-title: FEBS Lett. doi: 10.1016/0014-5793(88)80853-6 contributor: fullname: Endo – volume: 22 start-page: 15347354231198074 year: 2023 ident: ref_8 article-title: Quality of Life in Breast Cancer Patients Treated With Mistletoe Extracts: A Systematic Review and Meta-Analysis publication-title: Integr. Cancer Ther. doi: 10.1177/15347354231198074 contributor: fullname: Loef – volume: 321 start-page: 295 year: 1983 ident: ref_25 article-title: Mistletoe Toxicity publication-title: Lancet doi: 10.1016/S0140-6736(83)91706-3 contributor: fullname: Stirpe – ident: ref_15 – ident: ref_5 doi: 10.1186/s12906-020-03013-3 – volume: 44 start-page: 283 year: 2018 ident: ref_31 article-title: Protective effects of plant-derived flavonoids on hepatic injury publication-title: J. Funct. Foods doi: 10.1016/j.jff.2018.03.015 contributor: fullname: Wan – volume: 2014 start-page: 1 year: 2014 ident: ref_32 article-title: Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study publication-title: Evid.-Based Complement. Altern. Med. contributor: fullname: Steele – volume: 282 start-page: 186 year: 1981 ident: ref_27 article-title: Mistletoe hepatitis publication-title: BMJ doi: 10.1136/bmj.282.6259.186 contributor: fullname: Harvey – volume: 129 start-page: 229 year: 2019 ident: ref_29 article-title: Biochemical and morphological changes in mouse liver induced by mistletoe toxins publication-title: Food Chem. Toxicol. doi: 10.1016/j.fct.2019.04.044 contributor: fullname: Wieczorek – ident: ref_20 – volume: 5 start-page: 307 year: 2017 ident: ref_13 article-title: Intravenous application of Helixor® in gynecological oncology: Is it safe? publication-title: Int. J. Res. GRANTHAALAYAH doi: 10.29121/granthaalayah.v5.i10.2017.2306 contributor: fullname: Ji |
| SSID | ssj0057141 |
| Score | 2.3631487 |
| Snippet | Mistletoe lectins (ML) have cytotoxic and immunomodulating properties, and subcutaneously applied mistletoe products (MP) containing ML have approval for... |
| SourceID | doaj pubmedcentral proquest gale crossref pubmed |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 278 |
| SubjectTerms | Analysis Cancer Care and treatment Chemical properties Enzymes Health aspects Liver Mistletoe mistletoe lectins Pharmacokinetics phase I clinical trial Plant lectins reversible liver injury Ribonucleic acid RNA viscum album |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9swDBaGnnYZtu7lrRs0dOguNRrLetDHbFjRFt2QQwv0JkiyjAYFnGJJC-Tfl7ScxMYOu-yYSAJkkqI-2uRHxr6KqFUVg8awpKhzCS7kUEGRG2cqIeqKMAplW_zWZ9fy4kbdDFp9UU5YogdOgjuB2qnayRBLr6X3Brxogp9EAF9XpklMoIXaBFPJBytTyCKRkZYY1J_c3xZk2YKaqQ2un46l_29fPLiMxomSg5vn9CV70UNGPk1bfcWexXafHc0S5_T6mF_tSqiWx_yIz3Zs1OvXrE0_7xZ3iCdpCl80_Necvu6uFpFfksNrl7zrFc7PaQOPHW0rn-4-bdMSN1g0SzSxfN7yVMa05uiA6I3O8g27Pv159eMs75ss5AGDnVUuEf-BCTAJRPUunStqNfGy8VKapjSVh4hyayLq0pW6riQQRxjVryLWQ2dQvmV77aKN7xkXHgzoRmoNGqNug5Gc03oiXFMBOC8ydriRvb1PXBoWYxDSkN1pKGPfSS3bGcR_3f2BVmF7q7D_soqMfSOlWjqlKLjg-mID3CjxXdkpRv4CkYtRGTsYzcTTFcbDG7Ow_ele2pI64CmEbjj8ZTtMKyljrY2oJNuFroiHtcnYu2RF20cqQUkM1cqMwci-Rs88Hmnntx33NyUMKDTvD_9DSh_Zc4EYravQFwdsb_XnIX5CjLXyn7vj9AQaGCbK priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEBZpcuml9F23aVFpSS8xu5b18qlsSsK2tGEpCeQmJFlOloC9zTqB_fed8WO9ptCj9QBZ89CMNPMNIZ9ZkCILXoJbkuQx19bHOtNJrKzKGMsztFEw2uJczi_5jytxtUfmfS4MhlX2OrFR1Hnl8Y58kmLVMQHHpZhYh7cAvp58Xf2JsX4UvrN2xTQekQOWcHywPTg5PV_87rWyUNDawpOm4OZPVjcJ8jrD8mo7B1KD2_-vdt45nsahkztn0dlT8qQzIumspfozshfK5-Ro0aJQb47pxZBUtT6mR3Qx4FNvXpCy_bytbsHCxCG0KuivJb731lWgP1EFlmvaVA-n33EBDw2QK50Nj904xe5MWrTAsXRZ0jaxaUNBJeEdz_oluTw7vfg2j7uyC7EH96eOOViEWnk99Qj-zq1NcjF1vHCcqyJVmdMB9q0IQF2byjzjGlHDMKMVrD9QD-krsl9WZXhDKHNaaVlwKbUEP1yBb2elnDJbZFpbxyLyqd97s2rRNQx4JUghM1AoIidIlu0IRMRuGqq7a9MJmNG5FbnlPqROcueUdqzwbhq0dnmmCh6RL0hUg3KL3GO79ANYKCJgmZkCXwNsGSUicjgaCfLmx909W5hO3tdm4M6IfNx240yMYSsDEMk0zixYyFJF5HXLRdtfSrXg4LylEdEj_hr987inXN40aOAYQiCAvd_-f13vyGMG9liTjc8OyX59dx_egz1Vuw-dqPwFq9ohVg priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals (Open Access) dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwEB2VcuGCSvlKKZURqFwa2HUce3JAaEFUBVG0h67Um2UnDl0VJWV3Qey_ZybJfgQ4cExsS7FnbL8Xe94AvJBBp1nINdGSYRErdHmMGQ5j40wmZZExRuHbFl_02UR9ukwvd2CVv7MbwPk_qR3nk5rMvr369X35lib8G2acRNlf31wN2W-lwVtwW6pEsaefq_VpQmraDJYc1BWjVKaVKf2jbW9javT7_16lt7ap_hXKrT3pdA_udmBSjFrr34OdUO3D8bhVo16eiItNcNX8RByL8Uanenkfqvbxur4mpMlVRF2K8ymf-y7qID7zUljNRZNFXHzkD_jZCLqK0ebQm5u4rUbjVkBWTCvRBjgtBS1N_K9n_gAmpx8u3p_FXfqFOCcatIgVIUM0OQ5yFoFXzg2LdOBV6ZUyZWIyj4HGrQxkZZfoIlPI6mEc2UookJaJ5CHsVnUVHoOQHg3qUmmNmvi4IY7ntB5IV2aIzssInq_G3t60KhuW2AlbyG4sFME7Nsu6BitjNy_q2VfbTTSLhUsLp_KQeK28N-hlmftBQPRFZkoVwUs2qmWPooHLXReGQB_KSlh2ZIhzEKYxaQSHvZo07_J-8cot7MptbcK58VICdVT8bF3MLfkuWxXISLYhtYSUtYngUetF6y4lmCoicUkE2POvXp_7JdX0qlEF56sEKbn6wX938AnckQTRmgB9eQi7i9mP8JQg1sIfNfPnN3IXJBs priority: 102 providerName: Scholars Portal |
| Title | Pharmakokinetics of Mistletoe Lectins after Intravenous Application of a Mistletoe Product in Healthy Subjects |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38543063 https://www.proquest.com/docview/3003355845/abstract/ https://search.proquest.com/docview/3014005467 https://pubmed.ncbi.nlm.nih.gov/PMC10975571 https://doaj.org/article/8da5da4ce3b64bb78b2fcb0e88bd97f4 |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3Pb9MwFLa2ceGC-E1gVEagcVnWJnZs59hNnQaiU4U2aTfLdhxWjSXVWpB64W_nPSdpG3HjEimxLTl-79nfs9_7TMin1Iss906AW5IUMVfGxSpXSSyNzNO0yBGjYLTFpbi45l9vsps9IrpcmBC07-z8pPp5f1LNb0Ns5eLeDbs4seFseoanplkmk-E-2ZeMdT56M__Cd540RKQMHPrh4jZBrU4lXs3HVMYBJLPeKhTI-v-dknfWpH685M4CdP6UPGmRIx03PXxG9nz1nBzNGurp9TG92mZSLY_pEZ1tSanXL0jVvN7VdwArsQqtSzqd4yHvqvb0G8571ZKGK8PpF-zA78DeSsfbE25sYnYazRq2WDqvaJPNtKYwD-HGzvIluT6fXJ1dxO1dC7EDn2cVc4CBSjo1csj4zo1JimxkeWk5lyWTuVUehrD0IFLDRJFzhVRhmMYKkA_mBPaKHFR15d8QmlollSi5EEqA8y3BoTNCjFJT5koZm0bkYzf2etFQamhwRVBYeiusiJyiWDY1kAY7fKgffuhWGbQqTFYY7jyzglsrlU1LZ0deKVvksuQR-YxC1WisMHDOtDkH0FGkvdJjCQ4GABiZReSwVxOMzPWLO7XQrZEvNcOL8DJAcFD8YVOMLTFwrfIgJB08WIDFQkbkdaNFm1_qlDEiqqdfvX_ul4BFBArwzgLe_n_Td-RxCgAtpOenh-Rg9fDLvweAtbID8uh0cjn7PggbFPCccoXPP5NBsLS_0qcqPQ |
| link.rule.ids | 230,315,733,786,790,870,891,2115,2236,21416,24346,27957,27958,33779,33780,43840,53827,53829,74659 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9B9wAviG8CA4xA42XRmsSxnSfUoU0ddFWFOmlvlu04rJqUlKUg9b_nLkk_IiQeW9uS4zuf72ff_Q7gU-xFmnknEJZEeciVcaHKVBRKI7M4zjPyUSjaYirGV_zbdXrdXbjVXVjlxiY2hjqvHN2RnyRUdSzF4zL9svwVUtUoel3tSmjchwOeIFQZwMHp2XT2Y2OLUxnxqCUlTRDcnyxvItLwmIqq7R1DDVv_vzZ571DqB0zunUDnj-FR5zqyUSvrJ3DPl0_haNZyT6-P2XyXSlUfsyM227FSr59B2f68rW7Rr6QurCrY5YJeeVeVZxMyfGXNmprh7IIm8Kehb2Wj3RM3DTF7g2YtXSxblKxNZ1ozNER0s1M_h6vzs_nXcdgVWwgdgp5VyNEPVNKpoSPKd25MlKdDywvLuSwSmVnlcd0KjzI1icgzrogrjPJY0edDo5C8gEFZlf4VsNgqqUTBhVAC0bdERGeEGMamyJQyNg7g42bt9bLl1NCIRUhCeiehAE5JLNsexIPd_FHd_dTdttIqN2luuPOJFdxaqWxcODv0Stk8kwUP4DMJVdNuxYVzpks6wIkS75UeSUQY6MHINIDDXk_cZa7fvFEL3e3yWu90MoAP22YaSZFrpUch6QbCol8sZAAvWy3aflKiUo6QLQlA9fSr9839lnJx03CAU-BAiur9-v_zeg8PxvPLiZ5cTL-_gYcxemRNPn58CIPV3W__Fj2qlX3XbZu_xfsgiQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9BJyFeEN-EDTACjZdFbRLHdp5QB6s2GFWENmlvlp04rJqUdEtB6n_PXZI2jZB4TGxLtu_Dd_bd7wA-hk7EicsEuiVB7nNlMl8lKvClkUkY5gnZKBRtMRenl_zbVXzVxT_VXVjlRic2ijqvMrojH0dUdSzG4zIeF11YRPp19nl561MFKXpp7cpp3Ic9yXECI9g7PpmnPzd6OZYBD1qA0ggd_fHyOiBuD6nA2s6R1CD3_6ufdw6oYfDkzmk0ewyPOjOSTVu6P4F7rnwKh2mLQ70-Yhd9WlV9xA5Z2iNUr59B2X7eVDdoY1IXVhXsx4JefFeVY-ekBMuaNfXD2RlN4E8D5cqm_XM3DTE7g9IWOpYtStamNq0ZKiW65amfw-Xs5OLLqd8VXvAzdIBWPkebUMlMTTKCf-fGBHk8sbywnMsikolVDvetcEhfE4k84YpwwyinFe0_VBDRCxiVVeleAQutkkoUXAgl0BOX6N0ZISahKRKljA09-LDZe71s8TU0-iVEId1TyINjIsu2B2FiNz-qu1-6EzGtchPnhmcusoJbK5UNi8xOnFI2T2TBPfhERNUkubhxmekSEHCihIGlpxK9DbRmZOzBwaAnSlw2bN6whe4kvtY9f3rwfttMIymKrXRIJN24s2gjC-nBy5aLtkuKVMzRfYs8UAP-Gqx52FIurhs8cAoiiJG9X_9_Xu_gAUqMPj-bf9-HhyEaZ01qfngAo9Xdb_cGjauVfdtJzV9kIiTG |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmakokinetics+of+Mistletoe+Lectins+after+Intravenous+Application+of+a+Mistletoe+Product+in+Healthy+Subjects&rft.jtitle=Pharmaceuticals+%28Basel%2C+Switzerland%29&rft.au=Lederer%2C+Ann-Kathrin&rft.au=Rieger%2C+Sabine&rft.au=Schink%2C+Michael&rft.au=Huber%2C+Roman&rft.date=2024-02-22&rft.pub=MDPI+AG&rft.issn=1424-8247&rft.eissn=1424-8247&rft.volume=17&rft.issue=3&rft_id=info:doi/10.3390%2Fph17030278&rft.externalDocID=A788252175 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1424-8247&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1424-8247&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1424-8247&client=summon |